Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease of unknown etiology. It is
characterized by deposition of extracellular matrix proteins, like collagen and fibronectin in …

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease of unknown etiology
characterized by distorted distal lung architecture, inflammation, and fibrosis. The molecular …

Idiopathic pulmonary fibrosis (IPF) is a fatal fibrotic lung disease associated with unremitting
fibroblast activation including fibroblast-to-myofibroblast transformation (FMT), migration …

Pulmonary fibrosis is a chronic, progressive, incurable interstitial lung disease with high
mortality after diagnosis and remains a global public health problem. Despite advances and …

The opportunity of a multidisciplinary evaluation for the diagnosis of interstitial pneumonias
highlighted a major change in the diagnostic approach to diffuse lung disease. The new …

Introduction There is an unmet need for new treatments for idiopathic pulmonary fibrosis
(IPF). The oral preferential phosphodiesterase 4B inhibitor, BI 1015550, prevented a decline …

Fibrosis is the excessive deposition of extracellular matrix components, which results in
disruption of tissue architecture and loss of organ function. Fibrosis leads to high morbidity …

Pulmonary fibrosis (PF) is a disease-refractive lung condition with an increased rate of
mortality. The potential factors causing PF include viral infections, radiation exposure, and …

Mesenchymal stromal/stem cells (MSCs) have a great potential to proliferate, undergo multi‐
directional differentiation, and exert immunoregulatory effects. There is already much …

Idiopathic Pulmonary Fibrosis (IPF) is a severe fibrotic lung disease characterized by
excessive collagen deposition and progressive decline in lung function. Th2 T cell-derived …